Much of this earlier work was done in the laboratory of Max Bergmann, who spent the first several decades of the century defining these proteases.
Merck has a Cathepsin K inhibitor in Phase 3 clinical trials by the name of Odanacatib for an expected indication of osteoporosis.
Cathepsin A is an enzyme which is classified both as a cathepsin and a carboxypeptidase.